CUSIP: 503459604
What is CUSIP 503459604?
CUSIP 503459604 identifies LJPC - LA JOLLA PHARMACEUTICAL CO - COM PAR $.0001 2 in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Open recent reporting periods for CUSIP 503459604:
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2022 Q3 | 0 | $0 | -$53,857,000 | 0 | |
| 2022 Q2 | 16,883,918 | $53,857,003 | +$1,089,648 | $3.19 | 37 |
| 2022 Q1 | 16,494,972 | $70,431,274 | -$723,442 | $4.27 | 44 |
| 2021 Q4 | 16,737,185 | $77,825,563 | -$4,174,504 | $4.65 | 44 |
| 2021 Q3 | 17,780,491 | $70,939,779 | -$2,441,335 | $3.99 | 51 |
| 2021 Q2 | 18,361,700 | $78,585,321 | -$10,292,851 | $4.28 | 59 |
| 2021 Q1 | 20,791,737 | $88,153,113 | +$2,127,920 | $4.24 | 74 |
| 2020 Q4 | 20,340,507 | $78,922,026 | -$128,678 | $3.88 | 62 |
| 2020 Q3 | 20,367,198 | $82,067,411 | +$507,557 | $4.03 | 64 |
| 2020 Q2 | 20,191,489 | $86,007,135 | +$5,502,028 | $4.26 | 74 |
| 2020 Q1 | 18,898,994 | $79,373,762 | +$8,959,956 | $4.20 | 69 |
| 2019 Q4 | 19,552,299 | $76,836,766 | -$51,387,886 | $3.93 | 73 |
| 2019 Q3 | 24,855,468 | $218,907,700 | -$22,107,862 | $8.80 | 73 |
| 2019 Q2 | 27,307,537 | $252,397,930 | +$23,200,956 | $9.25 | 77 |
| 2019 Q1 | 25,401,782 | $163,398,713 | -$70,703,731 | $6.43 | 78 |
| 2018 Q4 | 31,288,325 | $295,494,316 | -$23,418,111 | $9.43 | 80 |
| 2018 Q3 | 33,282,583 | $669,977,036 | +$52,028,815 | $20.13 | 75 |
| 2018 Q2 | 26,420,197 | $770,711,392 | +$38,609,701 | $29.17 | 91 |
| 2018 Q1 | 25,103,513 | $747,596,219 | +$95,513,840 | $29.78 | 98 |
| 2017 Q4 | 21,671,783 | $697,451,459 | +$39,843,841 | $32.18 | 92 |
| 2017 Q3 | 23,821,204 | $828,494,536 | -$6,498,436 | $34.78 | 95 |
| 2017 Q2 | 24,111,272 | $717,952,134 | +$76,434,629 | $29.77 | 82 |
| 2017 Q1 | 22,501,974 | $671,891,030 | +$226,951,459 | $29.85 | 96 |
| 2016 Q4 | 15,918,221 | $279,081,656 | -$5,685,317 | $17.53 | 62 |
| 2016 Q3 | 16,098,330 | $382,887,182 | +$5,880,405 | $23.79 | 70 |
| 2016 Q2 | 15,972,246 | $255,675,832 | -$9,198,138 | $16.00 | 72 |
| 2016 Q1 | 16,134,183 | $337,146,000 | +$1,728,873 | $20.91 | 66 |
| 2015 Q4 | 15,932,309 | $430,390,906 | -$4,300,114 | $27.00 | 78 |
| 2015 Q3 | 16,084,261 | $446,797,865 | +$144,681,607 | $27.79 | 72 |
| 2015 Q2 | 10,873,590 | $266,508,413 | +$20,866,245 | $24.51 | 52 |
| 2015 Q1 | 10,079,423 | $184,459,660 | +$9,567,944 | $18.30 | 37 |
| 2014 Q4 | 9,553,084 | $176,251,000 | +$15,991,918 | $18.45 | 33 |
| 2014 Q3 | 7,497,961 | $72,055,000 | +$40,347,558 | $9.61 | 28 |
| 2014 Q2 | 3,302,137 | $30,310,000 | +$16,513,855 | $9.18 | 21 |
| 2014 Q1 | 1,453,162 | $15,694,000 | +$15,472,000 | $10.80 | 24 |